LIVIVO - Search results -

Search results

Result 1 - 10 of total 18

Search options

Article ; Online: Efficacy of Mandibular Advancement Device in the Treatment of Obstructive Sleep Apnoea by Evaluating Upper Airway Space Volume Using CBCT.

Verma, Aanchal / Jain, Sumeet

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

2023 Volume 33, Issue 10, Page(s) 1194–1197

Abstract: Objective: To evaluate the efficacy of mandibular advancement device as a treatment of mild to moderate obstructive sleep apnoea and to evaluate the change in upper airway space volume by using cone beam CT (CBCT).: Study design: In vivo ... ...

Abstract	Objective: To evaluate the efficacy of mandibular advancement device as a treatment of mild to moderate obstructive sleep apnoea and to evaluate the change in upper airway space volume by using cone beam CT (CBCT). Study design: In vivo observational study. Place and Duration of the Study: Department of Prosthodontics, Crown and Bridge, Sri Aurobindo College of Dentistry, Indore (M.P), India, from March 2017 to January 2021. Methodology: Patients with mild to moderate obstructive sleep apnoea patients using Berlin questionnaire were selected. Pre- and posttreatment-CBCT analysis was done to compare the changes in superior and inferior upper airway space before and after using mandibular advancement device. The pre and postoperative CBCT were also compared using a paired t-test for the quantitative variables. After two months, the patients were asked to complete a self-administered questionnaire to assess their sleep improvement, initial symptoms regression, and effectiveness of the mandibular advancement device. Results: On comparative evaluation of the pre- and post-CBCT, the mean score before the mandibular advancement device placement was found to be 7.77+2.79 cc, whereas the mean score after the mandibular advancement device placement was found to be 9.75+3.34 cc (p<0.001). Significant volumetric change was seen in upper airway space after receiving treatment for the two months. The patient noticed a substantial improvement in their sleep as well as a reduction in the original symptoms. Conclusion: This study showed statistically significant volumetric change in the upper airway space and reduction in their symptoms after treatment with the mandibular advancement device (MAD). Key words: Obstructive sleep apnoea syndrome (OSA), Continuous positive airway pressure (CPAP), Cone beam computed tomography, Mandibular advancement device (MAD), Upper airway volume.
MeSH term(s)	Humans ; Occlusal Splints ; Spiral Cone-Beam Computed Tomography ; Mandibular Advancement/methods ; Sleep Apnea, Obstructive/diagnostic imaging ; Sleep Apnea, Obstructive/therapy ; Sleep ; Treatment Outcome
Language	English
Publishing date	2023-10-06
Publishing country	Pakistan
Document type	Observational Study ; Journal Article
ZDB-ID	2276646-7
ISSN	1681-7168 ; 1022-386X
ISSN (online)	1681-7168
ISSN	1022-386X
DOI	10.29271/jcpsp.2023.10.1194
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6532: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Dietary, Herbal and Nutritional Interventions for Managing Rheumatoid Arthritis: A Review.

Verma, Aanchal / Dubey, Nandini / Agrawal, Anant / Goyal, Ahsas

Current pharmaceutical biotechnology

2023

Abstract: Rheumatoid arthritis (RA) is a systemic, inflammatory disease that affects joints and leads to progressive cartilage and bone deterioration. The susceptibility to RA is determined by genetic and environmental factors. Recently, many efforts have been ... ...

Abstract	Rheumatoid arthritis (RA) is a systemic, inflammatory disease that affects joints and leads to progressive cartilage and bone deterioration. The susceptibility to RA is determined by genetic and environmental factors. Recently, many efforts have been undertaken to develop natural compounds capable of reducing the symptoms of RA to avoid the negative effects of the current anti-inflammatory drugs. Interestingly, substantial data has revealed that nutritional, and herbal supplements may be effective adjuvants in reducing the symptoms of RA by influencing the pathogenic inflammatory processes. In this context, various kinds of food, phenolic substances, spices like ginger, and turmeric, several vitamins, and probiotics are reported to control the activity of inflammatory molecules implicated in the pathophysiology of RA and therefore, have proved successful in slowing the course of this arthritic illness. Therefore, the goal of this review article is to compile various findings on RA that have revealed illuminating information about the antiinflammatory, antioxidant, analgesic, immunomodulatory, and bone erosion-preventing properties of nutritional, and herbal components. Conclusively, this review concentrates on natural ingredients that may enhance overall well-being, promote health, and lessen the risk of RA.
Language	English
Publishing date	2023-08-07
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2132197-8
ISSN	1873-4316 ; 1389-2010
ISSN (online)	1873-4316
ISSN	1389-2010
DOI	10.2174/1389201024666230807155529
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6212: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Erucic Acid: A Possible Therapeutic Agent for Neurodegenerative Diseases.

Goyal, Ahsas / Dubey, Nandini / Verma, Aanchal / Agrawal, Anant

Current molecular medicine

2023

Abstract: Neurodegenerative disorders are among the most common life-threatening disorders among the elderly worldwide and are marked by neuronal death in the brain and spinal cord. Several studies have demonstrated the beneficial role of dietary fatty acids in ... ...

Abstract	Neurodegenerative disorders are among the most common life-threatening disorders among the elderly worldwide and are marked by neuronal death in the brain and spinal cord. Several studies have demonstrated the beneficial role of dietary fatty acids in different brain disorders. This is due to their neurotrophic, antioxidant, and anti-inflammatory properties. Furthermore, extensive evidence shows that an unbalanced intake of certain dietary fatty acids increases the risk of neuropsychiatric diseases. Several research has been done on erucic acid, an ingestible omega-9 fatty acid that is found in Lorenzo's oil. Erucic acid was previously thought to be a natural toxin because of its negative effects on heart muscle function and hepatic steatosis, but it has been discovered that erucic acid is regularly consumed in Asian countries through the consumption of cruciferous vegetables like mustard and rapeseed oil with no evidence of cardiac harm. Erucic acid can also be transformed into nervonic acid, a crucial element of myelin. Therefore, erucic acid may have remyelinating effects, which may be crucial for treating different demyelinating conditions. Also, erucic acid exerts antioxidant and anti-inflammatory effects, suggesting its possible therapeutic role in different neurodegenerative disorders. Considering the fruitful effects of this compound, this article reviews the probable role of erucic acid as a pharmacological agent for treating and managing different neurodegenerative disorders.
Language	English
Publishing date	2023-05-09
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2064873-X
ISSN	1875-5666 ; 1566-5240
ISSN (online)	1875-5666
ISSN	1566-5240
DOI	10.2174/1566524023666230509123536
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5580: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: High Mobility Group Box 1 Protein: A Plausible Therapeutic Molecular Target in Parkinson's disease.

Goyal, Ahsas / Agrawal, Anant / Dubey, Nandini / Verma, Aanchal

Current pharmaceutical biotechnology

2023

Abstract: Parkinson's disease (PD) is a widespread neurodegenerative disorder that exerts a broad variety of detrimental effects on people's health. Accumulating evidence suggests that mitochondrial dysfunction, neuroinflammation, α-synuclein aggregation and ... ...

Abstract	Parkinson's disease (PD) is a widespread neurodegenerative disorder that exerts a broad variety of detrimental effects on people's health. Accumulating evidence suggests that mitochondrial dysfunction, neuroinflammation, α-synuclein aggregation and autophagy dysfunction may all play a role in the development of PD. However, the molecular mechanisms behind these pathophysiological processes remain unknown. Currently, research in PD has focussed on high mobility group box 1 (HMGB1), and different laboratory approaches have shown promising outcomes to some level for blocking HMGB1. Given that HMGB1 regulates mitochondrial dysfunction, participates in neuroinflammation, and modulates autophagy and apoptosis, it is hypothesised that HMGB1 has significance in the onset of PD. In the current review, research targeting multiple roles of HMGB1 in PD pathology was integrated, and the issues that need future attention for targeted therapeutic approaches are mentioned.
Language	English
Publishing date	2023-09-05
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2132197-8
ISSN	1873-4316 ; 1389-2010
ISSN (online)	1873-4316
ISSN	1389-2010
DOI	10.2174/1389201025666230905092218
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6212: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Luteolin: Nature's promising warrior against Alzheimer's and Parkinson's disease.

Goyal, Ahsas / Solanki, Kunal / Verma, Aanchal

Journal of biochemical and molecular toxicology

2023 Volume 38, Issue 1, Page(s) e23619

Abstract: Neurodegenerative disorders (NDs) are defined as the slow loss of a group of neurons that are particularly sensitive. Due to the intricate pathophysiological processes underlying neurodegeneration, no cure exists for these conditions despite the ... ...

Abstract	Neurodegenerative disorders (NDs) are defined as the slow loss of a group of neurons that are particularly sensitive. Due to the intricate pathophysiological processes underlying neurodegeneration, no cure exists for these conditions despite the extensive research and advances in our knowledge of the onset and course of NDs. Hence, there is a medical need for the creation of a novel therapeutic approach for NDs. By focusing on numerous signaling pathways, some natural substances derived from medicinal herbs and foods have demonstrated potent activity in treating various NDs. In this context, flavonoids have recently attracted increased popularity and research attention because of their alleged beneficial effects on health. By acting as antioxidant substances, nutritional supplements made up of flavonoids have been found to lessen the extent of NDs like Alzheimer's disease (AD) and Parkinson's disease (PD). Luteolin is a flavone that possesses potent antioxidant and anti-inflammatory properties. As a consequence, luteolin has emerged as an option for treatment with therapeutic effects on many brain disorders. More research has focused on luteolin's diverse biological targets as well as diverse signaling pathways, implying its potential medicinal properties in several NDs. This review emphasizes the possible use of luteolin as a drug of choice for the treatment as well as the management of AD and PD. In addition, this review recommends that further research should be carried out on luteolin as a potential treatment for AD and PD alongside a focus on mechanisms and clinical studies.
MeSH term(s)	Humans ; Parkinson Disease/drug therapy ; Alzheimer Disease/drug therapy ; Alzheimer Disease/metabolism ; Antioxidants/pharmacology ; Antioxidants/therapeutic use ; Luteolin/pharmacology ; Luteolin/therapeutic use ; Flavonoids/therapeutic use
Chemical Substances	Antioxidants ; Luteolin (KUX1ZNC9J2) ; Flavonoids
Language	English
Publishing date	2023-12-13
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1410020-4
ISSN	1099-0461 ; 1095-6670
ISSN (online)	1099-0461
ISSN	1095-6670
DOI	10.1002/jbt.23619
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2201: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Exendin-4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease.

Verma, Aanchal / Chaudhary, Shobhit / Solanki, Kunal / Goyal, Ahsas / Yadav, Harlokesh Narayan

Chemical biology & drug design

2024 Volume 103, Issue 1, Page(s) e14426

Abstract: Neurodegenerative disorders, which affect millions worldwide, are marked by a steady decline of neurons that are selectively susceptible. Due to the complex pathological processes underlying neurodegeneration, at present, there is no viable therapy ... ...

Abstract	Neurodegenerative disorders, which affect millions worldwide, are marked by a steady decline of neurons that are selectively susceptible. Due to the complex pathological processes underlying neurodegeneration, at present, there is no viable therapy available for neurodegenerative disorders. Consequently, the establishment of a novel therapeutic approach for such conditions is a clinical void that remains. The potential significance of various peptides as neuroprotective interventions for neurodegenerative disorders is gaining increasing attention. In the past few years, there has been growing scientific interest in glucagon-like peptide-1 receptor agonists due to their claimed neuroprotective effects. Exendin-4 is a glucagon-like peptide-1 receptor agonist that is known to possess anti-diabetic effects and does not degrade for hours, making it a superior candidate for such disorders. Moreover, exendin-4's neuroprotective effects have been reported in several preclinical studies. Exendin-4's diverse therapeutic targets suggest its potential therapeutic uses in neurodegenerative ailments like Alzheimer's disease and Parkinson's disease and have garnered an increasing amount of attention. Given the substantial body of evidence supporting the neuroprotective potential of exendin-4 in various research models, this article is dedicated to exploring the promising role of exendin-4 as a therapeutic agent for the treatment and management of Alzheimer's disease and Parkinson's disease. This review draws insights from the findings of numerous preclinical and clinical studies to highlight the collective neuroprotective advantages of exendin-4 and the potential mechanisms that underlie its neuroprotective effects.
MeSH term(s)	Humans ; Exenatide/therapeutic use ; Parkinson Disease/drug therapy ; Glucagon-Like Peptide 1/agonists ; Glucagon-Like Peptide 1/metabolism ; Glucagon-Like Peptide 1/therapeutic use ; Alzheimer Disease/drug therapy ; Neuroprotective Agents/pharmacology ; Neuroprotective Agents/therapeutic use ; Neurodegenerative Diseases/drug therapy
Chemical Substances	Exenatide (9P1872D4OL) ; Glucagon-Like Peptide 1 (89750-14-1) ; Neuroprotective Agents
Language	English
Publishing date	2024-01-15
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2216600-2
ISSN	1747-0285 ; 1747-0277
ISSN (online)	1747-0285
ISSN	1747-0277
DOI	10.1111/cbdd.14426
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: An Insight into the Promising Therapeutic Potential of Chicoric Acid.

Goyal, Ahsas / Dubey, Nandini / Agrawal, Anant / Sharma, Rashmi / Verma, Aanchal

Current pharmaceutical biotechnology

2023

Abstract: The pharmacological treatments that are now recommended for the therapy of chronic illnesses are examined in a great number of studies to determine whether or not they are both safe and effective. Therefore, it is important to investigate various ... ...

Abstract	The pharmacological treatments that are now recommended for the therapy of chronic illnesses are examined in a great number of studies to determine whether or not they are both safe and effective. Therefore, it is important to investigate various alternative therapeutic assistance, such as natural remedies derived from medicinal plants. In this context, chicoric acid, classified as a hydroxycinnamic acid, has been documented to exhibit a range of health advantages. These include antiviral, antioxidant, anti-inflammatory, obesity-preventing, and neuroprotective effects. Due to its considerable pharmacological properties, chicoric acid has found extensive applications in food, pharmaceuticals, animal husbandry, and various other commercial sectors. This article provides a comprehensive overview of in vitro and in vivo investigations on chicoric acid, highlighting its beneficial effects and therapeutic activity when used as a preventative and management aid for public health conditions, including diabetes, cardiovascular disease, and hepatic illnesses like non-alcoholic steatohepatitis. Moreover, further investigation of this compound can lead to its development as a potential phytopharmaceutical candidate.
Language	English
Publishing date	2023-12-11
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2132197-8
ISSN	1873-4316 ; 1389-2010
ISSN (online)	1873-4316
ISSN	1389-2010
DOI	10.2174/0113892010280616231127075921
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6212: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Comprehensive Review on Therapeutic Potential of Chrysin in Brain Related Disorders.

Goyal, Ahsas / Singh, Geetanjali / Verma, Aanchal

CNS & neurological disorders drug targets

2022 Volume 22, Issue 6, Page(s) 789–800

Abstract: Brain disorders are currently one of the world's most serious and difficult health issues. These brain disorders are accountable for a massive number of morbidities and mortalities around the world. The current treatments of these disorders are ... ...

Abstract	Brain disorders are currently one of the world's most serious and difficult health issues. These brain disorders are accountable for a massive number of morbidities and mortalities around the world. The current treatments of these disorders are frequently accompanied by severe side effects and cause a detrimental effect on health. Recently, plant flavonoids have sparked a surge in public and scientific attention because of their alleged health-promoting impact and almost no adverse repercussions. Also, scientific research has shown that phytochemicals possess numerous neuroprotective properties under in vivo and in vitro conditions. Chrysin is a therapeutic phytochemical that falls under the class of flavonoids based on its structure. The biological activities and pharmacological effects of chrysin include anticancer, antioxidant, and anti-inflammatory activities as well as amyloidogenic and neurotrophic effects. These therapeutic abilities of chrysin are attributed to its structural diverseness arising in ring-A and lack of oxygenation in B and C rings. Several studies have highlighted the rising significance of chrysin in a variety of brain illnesses, like Alzheimer's disease, Parkinson's disease, depression, anxiety, brain tumours, epilepsy, multiple sclerosis, traumatic brain injury, spinal cord injury, and ischemic stroke. This study depicts the relationship of chrysin with different brain-related disorders and discusses the mechanisms responsible for the potential role of chrysin as a pharmacological agent for the treatment and management of different brain disorders based on the results of several preclinical studies and taking into account the therapeutic effects of the compound.
MeSH term(s)	Humans ; Antioxidants/therapeutic use ; Brain ; Flavonoids/pharmacology ; Flavonoids/therapeutic use ; Flavonoids/chemistry ; Brain Injuries, Traumatic/drug therapy
Chemical Substances	chrysin (3CN01F5ZJ5) ; Antioxidants ; Flavonoids
Language	English
Publishing date	2022-05-30
Publishing country	United Arab Emirates
Document type	Review ; Journal Article
ZDB-ID	2228394-8
ISSN	1996-3181 ; 1871-5273
ISSN (online)	1996-3181
ISSN	1871-5273
DOI	10.2174/1871527321666220602111935
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5892: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Preclinical Evidence-based Review on Therapeutic Potential of Eugenol for the Treatment of Brain Disorders.

Goyal, Ahsas / Solanki, Ashutosh / Verma, Aanchal

Current molecular medicine

2022 Volume 23, Issue 5, Page(s) 390–400

Abstract: The increasing morbidness of brain disorders and conditions, such as anxiety, stress, depression, Alzheimer's disease, Parkinson's disease, and others, have become severe. Although researchers have spent a significant amount of time examining these ... ...

Abstract	The increasing morbidness of brain disorders and conditions, such as anxiety, stress, depression, Alzheimer's disease, Parkinson's disease, and others, have become severe. Although researchers have spent a significant amount of time examining these diseases and providing many benefits, there are still limited drugs available to treat these disorders. Eugenol, a dietary component present in numerous plants and herbs, possesses various health benefits. In various preclinical studies, eugenol has provided significant protective effects against a variety of brain disorders. Thus, including eugenol in the diet can fight various diseases and ensure a healthy life. Considering the fruitful impact of this compound, this review focuses on the brain disorders in which eugenol was used, and summarizes the beneficial properties of eugenol and its role in treating various brain diseases.
MeSH term(s)	Humans ; Eugenol/pharmacology ; Eugenol/therapeutic use ; Alzheimer Disease ; Parkinson Disease/drug therapy ; Diet
Chemical Substances	Eugenol (3T8H1794QW)
Language	English
Publishing date	2022-05-27
Publishing country	Netherlands
Document type	Review ; Journal Article
ZDB-ID	2064873-X
ISSN	1875-5666 ; 1566-5240
ISSN (online)	1875-5666
ISSN	1566-5240
DOI	10.2174/1566524022666220525145521
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5580: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The PI3K-AKT pathway: A plausible therapeutic target in Parkinson's disease.

Goyal, Ahsas / Agrawal, Anant / Verma, Aanchal / Dubey, Nandini

Experimental and molecular pathology

2022 Volume 129, Page(s) 104846

Abstract: Parkinson's disease is a common progressive and multifactorial neurodegenerative disease, characterized by the loss of midbrain dopaminergic neurons. Numerous pathological processes including, inflammation, oxidative stress, mitochondrial dysfunction, ... ...

Abstract	Parkinson's disease is a common progressive and multifactorial neurodegenerative disease, characterized by the loss of midbrain dopaminergic neurons. Numerous pathological processes including, inflammation, oxidative stress, mitochondrial dysfunction, neurotransmitter imbalance, and apoptosis as well as genetic factors may lead to neuronal degeneration. With the emergence of aging population, the health problem and economic burden caused by PD also increase. Phosphatidylinositol 3-kinases-protein kinase B (PI3K-AKT) signaling pathway regulates signal transduction and biological processes such as cell proliferation, apoptosis and metabolism. According to reports, it regulates neurotoxicity and mediates the survival of neurons. Accumulating evidences indicate that some natural products can play a neuroprotective role by activating PI3K-AKT pathway, providing an effective resource for the discovery of potential therapeutic drugs. The current review provides an overview of the PI3K-AKT signaling pathway and review the relationship between this signaling pathway and PD.
MeSH term(s)	Humans ; Aged ; Proto-Oncogene Proteins c-akt/metabolism ; Parkinson Disease/drug therapy ; Phosphatidylinositol 3-Kinases/metabolism ; Neurodegenerative Diseases/drug therapy ; Neurodegenerative Diseases/metabolism ; Neurodegenerative Diseases/pathology ; Dopaminergic Neurons/metabolism ; Dopaminergic Neurons/pathology ; Neuroprotective Agents/pharmacology ; Neuroprotective Agents/therapeutic use ; Neuroprotective Agents/metabolism
Chemical Substances	Proto-Oncogene Proteins c-akt (EC 2.7.11.1) ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; Neuroprotective Agents
Language	English
Publishing date	2022-11-24
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	207655-x
ISSN	1096-0945 ; 0014-4800
ISSN (online)	1096-0945
ISSN	0014-4800
DOI	10.1016/j.yexmp.2022.104846
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 183: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Your last searches

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito